PUBLISHER: Grand View Research | PRODUCT CODE: 2067475
PUBLISHER: Grand View Research | PRODUCT CODE: 2067475
The global diabetes clinical trials market size was estimated at USD 5.1 billion in 2025 and is projected to reach USD 9.3 billion by 2033, growing at a CAGR of 7.9% from 2026 to 2033. The market is driven by the increasing prevalence of diabetes and its related complications, the growing expansion of clinical trials, and rising R&D investments by pharmaceutical and biotech companies.
Some other factors contributing to market growth include sedentary lifestyles, an aging population, and changes in dietary habits, all of which have escalated the demand for innovative therapeutic options. This has led to increased investment in clinical research aimed at enhancing glycemic control, minimizing complications, and improving patient outcomes.
The market growth is attributed to the rising demand for more advanced diabetic treatments, particularly in areas such as personalized medicine, combination therapies, and long-acting insulin formulations. The industry is also shifting towards a more patient-centric approach to treatment, with an increased focus on managing comorbidities, such as cardiovascular and renal issues, further boosting investments in clinical trials. In addition, support from regulatory bodies and increased funding from pharmaceutical and biotechnology companies are aiding in the market's growth.
Moreover, shifting trend towards decentralized and hybrid clinical trial models that enhance patient recruitment and retention rates. The incorporation of digital health technologies, such as wearable glucose monitors and remote patient monitoring systems, is improving data accuracy and overall trial efficiency. Emerging markets are also becoming attractive locations for clinical trials due to their cost-effectiveness and diverse patient populations.
Furthermore, technological advancements are expected to drive the market, with the integration of artificial intelligence, big data analytics, and real-world evidence significantly influencing trial design and execution. Innovations such as continuous glucose monitoring systems, closed-loop insulin delivery, and new drug classes, such as GLP-1 receptor agonists and SGLT2 inhibitors, are transforming treatment approaches. In addition, companies are increasingly forming collaborations, partnerships, and mergers to enhance their clinical pipelines and expand their global reach. The focus on innovation strategies aims to accelerate time-to-market, optimize trial protocols, and leverage precision medicine. Thus, the diabetes clinical trials market is expected to see new growth opportunities driven by technological innovation, evolving treatment paradigms, and a strong commitment to improving long-term patient outcomes. Such factors are expected to drive the market.
Global Diabetes Clinical Trials Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global diabetes clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and region: